Zai Lab (ZLAB)

• Market cap: $3.26B
• 1 day: 3.02%
• 5 days: -5.38%
• 1 month: -15.33%
• 3 months: 14.27%
• 6 months: 6.11%
• Year to date: 19.75%
• 1 year: 98.20%
• 5 years: -52.39%
• 10 years: 6.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Employees: 1,869

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

150% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]

38% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 34

35% more capital invested

Capital invested by funds: $1.09B [Q3] → $1.48B (+$383M) [Q4]

25% more funds holding

Funds holding: 102 [Q3] → 128 (+26) [Q4]

0.6% more ownership

Funds ownership: 4.55% [Q3] → 5.15% (+0.6%) [Q4]

77% less call options, than puts

Call options by funds: $2.92M | Put options by funds: $12.6M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $36 22% upside
• Avg. target: $47 59% upside
• High target: $55 85% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

JP Morgan Anupam Rama 16% 1-year accuracy 10 / 61 met price target	72% upside $51	Overweight Maintained	13 Mar 2025
Scotiabank Louise Chen 19% 1-year accuracy 23 / 120 met price target	85% upside $55	Sector Outperform Initiated	7 Mar 2025
B of A Securities David Lim 0 / 0 met price target	22% upside $36	Neutral Downgraded	3 Mar 2025